WASHINGTON, March 29, 2016 -- The Center for Information and Study on Clinical Research Participation (CISCRP) is pleased to announce its second AWARE for All event in the D.C. metropolitan area on April 20, 2016. This free program is designed to improve understanding about clinical research participation and promote dialogue by connecting patients, researchers, and members of the general public in the local community.
The event will be hosted at Howard University's Blackburn Center on Wednesday, April 20 from 5 to 8 p.m. in collaboration with Howard University, Howard University Hospital and Georgetown-Howard Universities Center for Clinical and Transitional Science (GHUCCTS). This program will feature free health screenings, informational exhibits, meaningful presentations from prominent D.C. medical professionals and researchers about various health conditions, and local patients involved in clinical research, as well as refreshments and prizes. Funding for this event is provided by PhRMA, EMD Serono, Howard University, Lupus Research Institute, Optimal Research, and other local and national health and advocacy organizations.
"The discovery of new treatments is not possible without volunteers participating in clinical research," said Jocelyn Ulrich, Assistant Vice President, Science and Regulatory Advocacy, PhRMA. "For this reason, it is critical to both educate the public about clinical research and celebrate those who have participated. AWARE for All is an opportunity for this type of community education and engagement, and we're proud to be sponsoring the program for a second year."
|
|||||
CISCRP has held more than 50 of these AWARE for All Clinical Research Education Events in cities around the world, bringing communities together in each destination for important conversations about clinical research and the important role it plays in each of our lives.
"There is a need for general education about the clinical research process including the risks, benefits, and the rights of participants. Ultimately, CISCRP hopes to empower patients and the public to make informed decisions about clinical research." explained Ken Getz, Founder and Chairman of the Board at CISCRP.
AWARE for All is a free event is open to the public; however, advanced registration is strongly encouraged through www.awareforall.org or by calling 1-877-MED-HERO (1-877-633-4370).
ABOUT CISCRP:
The Center for Information and Study (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process. CISCRP provides free education and outreach to the general public and patient communities. Visit www.CISCRP.org for more information or to support CISCRP's educational initiatives.
Editor's Note
Community partners include: the Arthritis Foundation, Association of Clinical Research Professionals, Bristol-Myers Squibb, Cancer Support Community, Emerson Clinical Research, Familia Con Diabetes, FDA Office of Minority Health, Fuerza Contra Alzheimer's, Georgetown University School of Nursing, The George Washington University School of Medicine and Health Sciences, HealthiVibe, Howard University Clinical Research Unit (CRU), Hudson Global, the Leukemia & Lymphoma Society, Lupus Research Institute, Men's Health Network, The National Coalition for Women with Heart Disease (WomenHeart), Parkinson's Disease Foundation, PhRMA, Society for Women's Health Research, US Against Alzheimer's, and Whitman Walker- AIDS Clinical Trials Group.
A photo accompanying this release is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=39613
CONTACT: Danielle Lavieri, CISCRP
Phone: 617-725-2750
[email protected]


Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Italy Fines Apple €98.6 Million Over App Store Dominance
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 



